juillet 28, 2010
Aurgalys issued today July26th, 2010, an new analyst report on BioAlliance.
- Acyclovir Lauriad®: the Company has engaged discussion with European regulatory agencies and obtained a registration slot
- S1 2010 record turnover: €21.3 M versus €4.1 M for the same period in 2009
Since our coverage initiated on June 19th, 2009, the stock increased 61% from €3.44 to €5.53 today.
Download our BioAlliance Analyst Report here (available in english only)
www.bioalliancepharma.com
juin 22, 2010
Paris, Tel-Aviv, Lausanne, Buenos Aires, June 22, 2010 – Aurgalys, a global provider for life sciences companies through corporate finance, business development and interim management services, is pleased to announce today the appointment of Dr Lila Drittanti as Aurgalys partner and the opening of Latin America offices.
Download our press release here ( english)
Télécharger notre communiqué de presse ici (français)
avril 07, 2010
Aurgalys issued today April 7th, 2010, an new analyst report on BioAlliance.
Since our coverage initiated on June 19th, 2009, the stock increased 69% from €3.44 to €5.81 today.
Given the recent Company newsflow with the approval of Setofilm in Europe, the approval of Loramyc in 13 new European countries, making it 26, the new partner Therabel for the commercialization of Loramyc and Setofilm in Europe, using a risk-adjusted NPV method, we confirm our BUY recommendation and we give a target price of €13.3 within 12 months. This value will bring the market capitalization to €171.5 compared to €74.9 M as of today.
Download our BioAlliance Analyst Report here (available in english only)
www.bioalliancepharma.com
janvier 22, 2010
Through our analysis we considered that for BioAlliance:
- Major milestones were met in 2009
- Two products are due to be launched in new markets
- Five products currently in clinical development including one which has completed phase III
We recommand a BUY for the stocks with a target price of €12 within one year
Download our BioAlliance Coverage here (available in english only)
www.bioalliancepharma.com
décembre 15, 2009
December 15th, 2009, Aurgalys and Cukierman & Co Life Sciences Cukierman & Co. Life Sciences annouces that they have successfully advised Swiss company Evolva [SIX: EVE] in a CHF21M financial round
Download our English Press Release here